The IL-23 inhibitor from AbbVie indicated for the treatment of adults with
active psoriatic arthritis (PsA) and for moderate to severe plaque psoriasis (Ps)
in adults who are candidates for systemic therapy or phototherapy.1

IDENTIFYING BIO-NAïVE
PATIENTS WITH PsA

WHO MAY BE READY TO START
ON SKYRIZI

ARE YOUR BIO-NAÏVE PATIENTS READY FOR SKYRIZI?

Clinical experts Dr. Schwartzman and Dr. Khattri explore the KEEPsAKE 1 PsA trial and how to determine when a bio-naïve patient might be ready to start on SKYRIZI, as well as other topics, including:

  • GRAPPA recommendations of treatments for PsA include IL-23 inhibitors just like TNF and IL-17 inhibitors
  • Overview of bio-naïve patients enrolled in KEEPsAKE 1 PsA trial

MEET THE KEY OPINION LEADERS

SERGIO SCHWARTZMAN, MD

Dr. Schwartzman completed an internship and residency in internal medicine at Long Island Jewish Medical Center in New Hyde Park, New York, and fellowships in the Division of Rheumatic Diseases at New York Hospital and the Hospital for Special Surgery.

Dr. Schwartzman is a member of the American College of Rheumatology, the Spondyloarthritis Research & Treatment Network, the American Uveitis Society, and the Group for Research and Assessment of Psoriasis. He is the Franchellie M. Cadwell Emeritus chair at the Hospital for Special Surgery, Associate Attending Physician at the New York Presbyterian Hospital, and Associate Professor Medicine at Weill Cornell Medical Center.

He is currently in private practice in New York City and has over 34 years of experience and focus in the areas of PsA, RA, AS, autoimmune eye disease, and IBD-associated arthritis.

Dr. Sergio Schwartzman.
Dr. Saakshi Khattri.

SAAKSHI KHATTRI, MD

Dr. Saakshi Khattri is a board-certified rheumatologist, dermatologist, and internist and one of only a handful of triple-board-certified physicians across the United States.

After completing her MBBS from Delhi University, Dr. Khattri moved to New York to complete her internal medicine residency followed by a fellowship in rheumatology at the Albert Einstein College of Medicine in New York. She completed a 2-year research fellowship at Rockefeller University where she conducted research and ran clinical trials in atopic dermatitis and psoriasis under the mentorship of Dr. Emma Guttman and Dr. James Krueger.

Dr. Khattri then successfully completed a residency in dermatology at the Icahn School of Medicine at Mount Sinai.


ACR20/50/70 RESPONSE RATES

In patients with PsA at Week 24 and ~3 years1-3

Primary endpoint ACR20 at 24 weeks1

WELL-STUDIED SAFETY PROFILE

Across PsA & Ps1